Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321647 | 0.88 | DRD2 (0.36) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL6683679 | 0.82 | MAOA (0.38) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL23832876 | 0.81 | MAOA (0.41) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL6684825 | 0.81 | MAOA (0.37) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL29709012 | 0.81 | MAOA (0.49) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL31127765 | 0.81 | MAOA (0.33) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL13451249 | 0.81 | MAOA (0.33) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL29961435 | 0.81 | MAOA (0.33) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL21098729 | 0.81 | MAOA (0.49) | MAOAMAOBCYP2A6MEN1KMT2A | |
| SCHEMBL21098689 | 0.77 | EGFR (0.41) | MAOAMAOBMEN1KMT2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4619386-A1 | ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-12365695-B2 | Fused ring heteroaryl compounds as RIPK1 inhibitors | BISICHEM CO., LTD. (KR) | 2025-07-22 | — | — | US | disclosed |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119630672-A | Camptothecin derivative and conjugate thereof, and preparation method and medical application thereof | 一线医药（杭州）有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118852123-A | Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2024-10-29 | — | — | CN | disclosed |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-115298165-B | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147771-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1831159-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC | 2006-07-27 | — | — | US | disclosed |
| WO-2006066790-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | INSRR, TTN, INSR | MAOA 1333/4885MAOB 1440/4885CYP2A6 823/4885 |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | MAOA 4048/4885MAOB 4215/4885CYP2A6 2375/4885 |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | MAOA 4048/4885MAOB 4215/4885CYP2A6 2375/4885 |
| US-12365695-B2 | Fused ring heteroaryl compounds as RIPK1 inhibitors | RIPK1, RIPK3, RIPK4 | MAOA 4369/4885MAOB 4397/4885CYP2A6 3893/4885 |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | HTR2A, HTR1A, HTR5A | MAOA 153/4885MAOB 137/4885CYP2A6 341/4885 |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | MAOA 4048/4885MAOB 4215/4885CYP2A6 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.